Premium biotech news in 2022? BioTech Health X brings you the latest most reliable biotech news including breaking news on the latest biotechnology research, emerging companies, biotech acquisitions, funding deals and other industry analysis. Our coverage not only includes study news and site updates from researchers but also financial analysis of the high and low daily market including several of the last market moves, first opening market updates, top share tips and more. Get everything you need delivered straight to your Inbox with our newsletter based on the science research and stories you want to read and follow from our team. Sign up for free today!
Toyobo Co., Ltd. has launched a major U.S. marketing initiative for Nerbridge TM (“the product”, hereafter), a conduit for peripheral nerve regeneration. On January 11, 2022, Toyobo kicked off the sales promotion campaign at a conference jointly held in Carlsbad, California, by three societies – the American Association for Hand Surgery (AAHS), the American Society for Peripheral Nerve (ASPN) and the American Society for Reconstructive Microsurgery (ASRM). The campaign is being conducted in partnership with the exclusive U.S. distributor of Nerbridge TM, Synovis Micro Companies Alliance, Inc. (hereafter Synovis), a subsidiary of Baxter International Inc., a global medtech leader. Toyobo plans to enhance the production capacity of the product by the end of 2025 as well as expanding the scope of its clinical applications. To respond to the increasing demand expected for nerves conduits in the U.S. and elsewhere in the world, Toyobo will strengthen its production and sales capacities, thus becoming the leading company in the nerve conduit business field.
Though clinical trials in the DMD space have progressed, CureDuchenne is aware of the limitations these therapies present. This has driven our global strategy. That’s what FUTURES is going to lay out for the parents and for the families. They’ll see for the first time where we are in gene therapy, the estimate on when these drugs are likely to be approved, and then what’s next. He explained that Adeno-associated virus (AAV) delivery has packing capacity limitations, but Code’s platform does not, which opens the door to formerly impossible investigations. The treatment can be re-dosed, as well. If their technology platform is successful, it has the ability to transform the way we think about delivering much larger gene transcripts and re-dosing.
Biotech Health X delivers the latest research and biotechnology news to help keep you informed on the powerful tools and medicine being developed by scientists, university research programs, new study data and other information linked to humans genes structure and identify the advantage that technology plays in nature and our modern world. From first time breakthrough reports or initial lab studies on mice our team helps to provide coverage and assess the collaboration that exists in the biotechnology field. Read more information on https://biotechhealthx.com/.
There are several factors that are helping to drive the growth of the global passive prosthetics market. One of the biggest driving factors in the growing number of accidents and mishaps that lead to some form of physical disability. Moreover, the growing demand for such passive prosthetics in the cosmetics industry is also helping to drive the growth of the market. In recent years, people have become more aware about the treatment techniques and the benefits offered by the passive prosthetics. This has significantly helped in increasing the popularity of the market among the masses. Moreover, the constant developments and advancements in the healthcare sector are also helping the market growth. Both public and private sector investments are helping the passive prosthetics manufacturers to develop new and affordable products that will cater to the wide range of demands across the globe.